AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:185 | Increase, Mutations |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:1392 | Oxidative Stress |
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:116 | Activation, FAS |
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.14 | KE:768 | Increase, Cytotoxicity |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:1271 | Activation of TGF-β signaling |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1392 | Oxidative Stress |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.29 | KE:1636 | Increase, Chromosomal aberrations |
KE:185 | Increase, Mutations |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1669 | Increased, DNA damage and mutation |
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1283 | Activation, TGF-beta pathway |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.12 | KE:1669 | Increased, DNA damage and mutation |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1669 | Increased, DNA damage and mutation |
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1669 | Increased, DNA damage and mutation |
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway |
AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary System Disease | Under Development | 0.2 | KE:1392 | Oxidative Stress |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.05 | KE:1392 | Oxidative Stress |
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.06 | KE:1392 | Oxidative Stress |
AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural Tube Defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1669 | Increased, DNA damage and mutation |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.09 | KE:1392 | Oxidative Stress |
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1392 | Oxidative Stress |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1392 | Oxidative Stress |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.09 | KE:1392 | Oxidative Stress |
AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous System Disease | - | 0.05 | KE:1392 | Oxidative Stress |
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.3 | KE:185 | Increase, Mutations |
KE:1392 | Oxidative Stress |
KE:1636 | Increase, Chromosomal aberrations |
AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.14 | KE:1392 | Oxidative Stress |
AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal System Disease | Under Review | 0.14 | KE:1392 | Oxidative Stress |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.09 | KE:2124 | increased, Bax expression |
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:1392 | Oxidative Stress |
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:1392 | Oxidative Stress |
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:1392 | Oxidative Stress |
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.12 | KE:2171 | Activated BMP/TGF-beta pathway |
KE:1392 | Oxidative Stress |
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:2124 | increased, Bax expression |